# US 2004/0082065 A1 · Use of stimulated peripheral-blood mononuclear cells for the treatment of cancerous diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082065 A1
- Document ID: US20040082065A1
- Status: Published application
- Kind: A1
- Application number: 10/687,913
- Filed: 2003-10-20
- Published: 2004-04-29
- Earliest claimed: 2001-04-26
- Inventors: Rudolf Wank
- Web page: https://patentgrep.com/patent/US20040082065A1

## CPC

- A61K 40/10: characterised by the cell type used
- A61P 35/00: Antineoplastic agents
- A61K 40/42: Cancer antigens
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2239/31: characterized by the route of administration
- A61K 2239/49: Breast
- A61K 2239/50: Colon
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of peripheral-blood mononuclear cells that have been stimulated via cascade priming (CAPRI cells) for the purpose of providing an agent for the treatment of cancerous diseases. The CAPRI cells may also be administered in combination with CD3-activated cells.

## Claims

### Claim 1

Use of peripheral-blood mononuclear cells that have been stimulated via cascade priming (capri cells), which are obtainable by the following stimulation process:
peripheral-blood mononuclear cells (PBMC) are subjected to primary stimulation by means of agents that stimulate T-lymphocytes
naïve PMBC are added to the PBMC that have been subjected to primary stimulation and are incubated for the purpose of stimulating the naïve PBMC, for the purpose of providing an agent for the treatment of cancerous diseases.

### Claim 2 (depends on 1)

Use according to claim 1, characterised in that use is made of autologous or allogenic CAPRI cells.

### Claim 3 (depends on 1, 2)

Use according to one of claims 1 or 2, characterised in that the PBMC are subjected to primary stimulation by means of CD3 antibodies and/or B7 antibodies and/or lectins and/or calcium ionophores and/or allogenic cells and/or xenogenic cells.

### Claim 4 (depends on 3)

Use according to claim 3, characterised in that the PBMC are subjected to primary stimulation by means of CD3 antibodies.

### Claim 5 (depends on 4)

Use according to claim 4, characterised in that the PBMC are subjected to primary stimulation by means of immobilised CD3 antibodies.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Use according to one of claims 1-5, characterised in that primary stimulation of the PBMC and/or stimulation of the naïve PBMC is undertaken in the presence of interleukin-2 and/or interleukin-4 and/or interferon-γ.

### Claim 7 (depends on 1, 2, 3, 4, 5)

Use according to one of claims 1-5, characterised in that the ratio of PBMC subjected to primary stimulation to naïve PBMC is between 1:10 and 10:1.

### Claim 8 (depends on 7)

Use according to claim 7, characterised in that the ratio of PBMC subjected to primary stimulation to naïve PBMC is 1:1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Use according to one of claims 1-8, characterised in that the CAPRI cells are administered by means of an injection intradermally, intravenously and/or intramuscularly and/or in or around the tumour.

### Claim 10 (depends on 9)

Use according to claim 9, characterised in that the CAPRI cells are administered by means of an injection intradermally and intravenously.

### Claim 11 (depends on 9, 10)

Use according to one of claims 9 or 10, characterised in that the CAPRI cells are administered in a dosage of 0.5-30 million cells per injection.

### Claim 12 (depends on 11)

Use according to claim 11, characterised in that the CAPRI cells are administered in a dosage of 1-20 million cells per injection.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use according to one of claims 1-12, characterised in that the CAPRI cells are administered together with CD3-stimulated lymphocytes.

### Claim 14 (depends on 13)

Use according to claim 13, characterised in that the CD3-stimulated lymphocytes are administered in a dosage of 1-20 million cells per injection.

### Claim 15 (depends on 13, 14)

Use according to one of claims 13 or 14, characterised in that the CD3-stimulated lymphocytes are administered by means of an injection intradermally and/or intramuscularly.

### Claim 16 (depends on 13, 14, 15)

Use according to one of claims 13-15, characterised in that the CD3-stimulated lymphocytes are administered into a different place in the body of the patient than the CAPRI cells.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use according to one of claims 1-16, characterised in that it is undertaken together with a medicinal or radiotherapeutic treatment that is matched to the type of disease.
